News
PerkinElmer Purchases GE Healthcare’s Catalog Radiochemicals, SPA Reagents and Cytostar-T Plate Assets
PerkinElmer adds offerings for detection and screening of potential new drugs, expands radiolabeling and bead-based assay technologies
PerkinElmer, Inc. recently announced that it has purchased the asset of GE Healthcare’s 3H and 14C Catalog Radiochemicals, Scintillation Proximity Assay (SPA) reagents and Cytostar-T plate product lines.
The Catalog Radiochemical products are used for a variety of research applications, including screening of potential drug candidates through binding assays. The SPA bead-based light-emitting assay and Cytostar-T plate technologies are offerings that enable the automation of High Throughput Screening (HTS) processes, to help drug discovery researchers quickly and accurately determine if potential new drug compounds are effective against their intended disease targets.
As a result of this asset purchase, PerkinElmer will now provide the world’s largest selection of high-quality radiolabeled compounds to the global scientific community.
GE Healthcare will be working closely with PerkinElmer to ensure a smooth transition of its manufacturing and technical support activities and to minimize disruption for customers during the transition period. BU sourcing will also monitor the transition and aggressively manage cost, quality and delivery concerns with PerkinElmer.